Chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer

Yutaka Ogasawara, Hiroyoshi Doihara, Mina Takahashi, Kensuke Kawasaki, Naruto Taira

Research output: Contribution to journalArticle

Abstract

PURPOSE: We evaluated chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer. PATIENTS & METHODS: Retrospectively, we evaluated 27 patients who received chemotherapy after second line chemotherapy. RESULTS: Eighteen patients received anthracycline(A)and/or taxane(T)containing chemotherapy regimens, 16 patients received chemotherapy regimens containing anticancer drugs except A and T, and 13 patients received oral fluoropyrimidines. Of all 48 chemotherapy regimens, 15(31.4%)regimens demonstrated response to chemotherapy. The clinical response rate was statistically equal among each chemotherapy regimen, and whenever patients received chemotherapy in any line. In univariate analysis, hormone receptor status, ECOG performance status(PS), and response to the first- or second-line chemotherapy were significantly associated with clinical response to chemotherapy after second-line chemotherapy. In multivariate analysis, only hormone receptor was significant. For overall survival according to response to first- or second-line chemotherapy, the difference was not significant. Meanwhile, overall survival according to response to chemotherapy after second-line chemotherapy was significant. CONCLUSIONS: Chemotherapy after second-line chemotherapy demonstrated a response similar to any regimen or any line. Patients having negative hormone receptor should receive chemotherapy after second-line chemotherapy.

Original languageEnglish
Pages (from-to)1713-1716
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume35
Issue number10
Publication statusPublished - Oct 2008

Fingerprint

Breast Neoplasms
Drug Therapy
Hormones
Survival
Anthracyclines
Multivariate Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer. / Ogasawara, Yutaka; Doihara, Hiroyoshi; Takahashi, Mina; Kawasaki, Kensuke; Taira, Naruto.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 35, No. 10, 10.2008, p. 1713-1716.

Research output: Contribution to journalArticle

@article{66607a7064224a25830a33e431399e91,
title = "Chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer",
abstract = "PURPOSE: We evaluated chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer. PATIENTS & METHODS: Retrospectively, we evaluated 27 patients who received chemotherapy after second line chemotherapy. RESULTS: Eighteen patients received anthracycline(A)and/or taxane(T)containing chemotherapy regimens, 16 patients received chemotherapy regimens containing anticancer drugs except A and T, and 13 patients received oral fluoropyrimidines. Of all 48 chemotherapy regimens, 15(31.4{\%})regimens demonstrated response to chemotherapy. The clinical response rate was statistically equal among each chemotherapy regimen, and whenever patients received chemotherapy in any line. In univariate analysis, hormone receptor status, ECOG performance status(PS), and response to the first- or second-line chemotherapy were significantly associated with clinical response to chemotherapy after second-line chemotherapy. In multivariate analysis, only hormone receptor was significant. For overall survival according to response to first- or second-line chemotherapy, the difference was not significant. Meanwhile, overall survival according to response to chemotherapy after second-line chemotherapy was significant. CONCLUSIONS: Chemotherapy after second-line chemotherapy demonstrated a response similar to any regimen or any line. Patients having negative hormone receptor should receive chemotherapy after second-line chemotherapy.",
author = "Yutaka Ogasawara and Hiroyoshi Doihara and Mina Takahashi and Kensuke Kawasaki and Naruto Taira",
year = "2008",
month = "10",
language = "English",
volume = "35",
pages = "1713--1716",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "10",

}

TY - JOUR

T1 - Chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer

AU - Ogasawara, Yutaka

AU - Doihara, Hiroyoshi

AU - Takahashi, Mina

AU - Kawasaki, Kensuke

AU - Taira, Naruto

PY - 2008/10

Y1 - 2008/10

N2 - PURPOSE: We evaluated chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer. PATIENTS & METHODS: Retrospectively, we evaluated 27 patients who received chemotherapy after second line chemotherapy. RESULTS: Eighteen patients received anthracycline(A)and/or taxane(T)containing chemotherapy regimens, 16 patients received chemotherapy regimens containing anticancer drugs except A and T, and 13 patients received oral fluoropyrimidines. Of all 48 chemotherapy regimens, 15(31.4%)regimens demonstrated response to chemotherapy. The clinical response rate was statistically equal among each chemotherapy regimen, and whenever patients received chemotherapy in any line. In univariate analysis, hormone receptor status, ECOG performance status(PS), and response to the first- or second-line chemotherapy were significantly associated with clinical response to chemotherapy after second-line chemotherapy. In multivariate analysis, only hormone receptor was significant. For overall survival according to response to first- or second-line chemotherapy, the difference was not significant. Meanwhile, overall survival according to response to chemotherapy after second-line chemotherapy was significant. CONCLUSIONS: Chemotherapy after second-line chemotherapy demonstrated a response similar to any regimen or any line. Patients having negative hormone receptor should receive chemotherapy after second-line chemotherapy.

AB - PURPOSE: We evaluated chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer. PATIENTS & METHODS: Retrospectively, we evaluated 27 patients who received chemotherapy after second line chemotherapy. RESULTS: Eighteen patients received anthracycline(A)and/or taxane(T)containing chemotherapy regimens, 16 patients received chemotherapy regimens containing anticancer drugs except A and T, and 13 patients received oral fluoropyrimidines. Of all 48 chemotherapy regimens, 15(31.4%)regimens demonstrated response to chemotherapy. The clinical response rate was statistically equal among each chemotherapy regimen, and whenever patients received chemotherapy in any line. In univariate analysis, hormone receptor status, ECOG performance status(PS), and response to the first- or second-line chemotherapy were significantly associated with clinical response to chemotherapy after second-line chemotherapy. In multivariate analysis, only hormone receptor was significant. For overall survival according to response to first- or second-line chemotherapy, the difference was not significant. Meanwhile, overall survival according to response to chemotherapy after second-line chemotherapy was significant. CONCLUSIONS: Chemotherapy after second-line chemotherapy demonstrated a response similar to any regimen or any line. Patients having negative hormone receptor should receive chemotherapy after second-line chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=55449129459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55449129459&partnerID=8YFLogxK

M3 - Article

C2 - 18931574

AN - SCOPUS:55449129459

VL - 35

SP - 1713

EP - 1716

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 10

ER -